Dividends & Income
To screen ETFs by asset class, performance, yield and more, check out the
View as an RSS Feed
View James Stoker's Comments
An Update For Gilead Sciences
Another weak piece of so called journalism again by STD. Author even tries to defend what?
Dec 2, 2014. 04:51 PM
Link to Comment
Sovaldi And Drug Pricing: The United States Of Saps
Just read the economist article and it seems a long way off before the US admin gets to grips with their healthcare costs. In the meantime GILD has the best offering and it´s just a great tech company. It is difficult to imagine that the stock price PE will remain so low. It´s a case of when it breaks out not if it breaks out. In the meantime it´s time for steady average price accumulation. The algos are driving the price . It´s a classic algo stock. Good intraday movement, high volume. I can envisage a 4-8% gap up driving GILD over the 84.88 all time high and then the charties come in with volume, a short squeeze happens and we´re moving quickly to 3 figures. The build up weeks leading to 22nd July when earnings are forecast will be interesting. Despite supposed competition coming to the market fast track the relative strength of GILD is good. Always buyers on weekness and the stock buyback programme helps give the stock a floor.
It can all happen differently. My world cup predictions have. But the fundamentals, the pipeline, the management, the cash position, the sharebuyback, the Sovaldi results Q1 speak for themselves.
I´m long GILD have been watching the stock for over 8 years and will be longer in the coming weeks.
Jun 19, 2014. 07:43 AM
Link to Comment
Xignite quote data
© 2015 Seeking Alpha